Novartis has reported positive outcomes from the multi-centre Phase IIIB APPULSE-PNH study of oral Fabhalta (iptacopan) in adults with paroxysmal nocturnal haemoglobinuria (PNH). These findings are ...

In 2008, Novartis bought 25% of Alcon from fellow Swiss company Nestlé. Two years later, it exercised its option to buy 52% for $28.1 billion before gaining full ownership in 2011. Drug Acquired From ...

Novartis in Focus. Based in Basel, Novartis (NVS) is in the Medical sector, and so far this year, shares have seen a price change of 21.05%. Currently paying a dividend of $2.6 per share, the ...

Failures at Novartis have prompted U.K. marketing watchdog the PMCPA to warn that “companies should be on high alert” when working with third parties to promote materials about medical ...

Reno, Nevada (UroToday.com) -- Novartis announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial. The trial met its primary endpoint with a statistically ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! Today, STAT’s Matthew Herper chats with J&J’s R&D chief, we ...

On Monday, Novartis (NYSE:NVS) announced positive topline results from the Phase III PSMAddition trial, which showed that its targeted radioligand therapy/RLT, Pluvicto (lutetium (177Lu ...

Novartis said Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The Swiss pharmaceutical company on Monday said Pluvicto showed ...

FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an ...

Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an earlier disease stage ...

Novartis is hoping that Scemblix (asciminib) will become the physician’s first choice of therapy for chronic myeloid leukaemia in chronic phase (CML-CP) after it has shown to be more tolerable than ...